Clinical trials: For Oncologic Patients
Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
This study is designed to determine the efficacy and safety of durvalumab and/or novel oncology therapies, with or without chemotherapy, for first-line Stage IV Non-Small Cell Lung Cancer (NSCLC)
- Trial name
- MAGELLAN (NCT03819465)
- Testing
- Durvalumab, Danvatirsen, Oleclumab
- Where
- 41 sites in United States, Austria and 7 more
- Volunteers
- 175 people
- Sponsor
- AstraZeneca
Patients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLC, EGFR Mutation-negative and ALK Rearrangement-negative
Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study
The treatment decisions, assessment schedule, and study procedures in this research will adhere to the routine clinical practice of each participating center.
- Conditions
- Patients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLC, EGFR Mutation-negative and ALK Rearrangement-negative, Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score of 0 to 2, No Prior Systemic Therapy Received for the Advanced or Metastatic Disease
- Trial name
- PROMISE (NCT07696832)
- Testing
- Ivonescimab Injection
- Where
- China
- Volunteers
- 265 people
- Sponsor
- Guangdong Association of Clinical Trials
Peripheral T-cell Lymphoma
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Prospective, longitudinal, multinational, observational study that will collect data on how patients with peripheral T-cell lymphoma (PTCL) are treated in academic and community practices.
- Trial name
- COMPLETE (NCT01110733)
- Where
- 68 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- Acrotech Biopharma Inc.
Leukemia
Ultrasound Use for Difficult Lumbar Punctures in Pediatric Oncology Patients
Hematology-oncology patients may require frequent lumbar puncture for diagnosis, assessment and therapy. When LP is difficult, the patient may endure multiple attempts, prolonged anesthesia time, and with failure of LP may…
- Trial name
- NCT01643291
- Testing
- Ultrasound
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Nationwide Children's Hospital
Cancer
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab
The rationale of the ROSY-D study is to continue to provide study treatment for patients who have participated in a parent study with Durvalumab and who are continuing to derive clinical benefit from treatment at the end of such…
- Trial name
- ROSY-D (NCT05303532)
- Testing
- Durvalumab
- Where
- 123 sites in United States, Argentina and 29 more
- Volunteers
- 214 people
- Sponsor
- AstraZeneca
Stereotactic Body Radiation Therapy (SBRT), Oligometastasis
SMC Radiation Oncology SABR Cohort for Oligometastasis
The goal of this observational study is to evaluate the efficacy and safety of stereotactic body radiotherapy (SABR) in patients with oligometastatic or oligoprogressive cancer. The main questions it aims to answer are: 1.
- Conditions
- Stereotactic Body Radiation Therapy (SBRT), Oligometastasis, Oligoprogression, ctDNA
- Trial name
- SABR-OMOP (NCT07121335)
- Testing
- Stereotactic body radiotherapy (SBRT)
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Samsung Medical Center
Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumor
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
CVM-1118 (TRX-818) is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines.
- Conditions
- Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumor, Gastro-enteropancreatic Neuroendocrine Tumor, Lung Neuroendocrine Neoplasm
- Trial name
- NCT03600233
- Testing
- CVM-1118
- Where
- 8 sites in Taiwan
- Volunteers
- 34 people
- Sponsor
- TaiRx, Inc.
Oncology
Personalized Functional Profiling in Metastatic Gastrointestinal Cancer or Recurrent Glioblastoma Patients in Luxembourg.
The investigators are developing a novel standardized and centralized approach named Integrated Personalized Functional Profiling (PFP) in Luxembourg.
- Trial name
- NCT03997617
- Testing
- Personalized Functional Profiling
- Where
- 2 sites in Luxembourg
- Volunteers
- 57 people
- Sponsor
- Luxembourg Institute of Health
Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung
Study of the Fixation of Various Vectors in PET/CT in Patients With a With Lung Cancer Before and During of CRT or RT
Study of the modification of the fixation(binding) of Fluoro-2-deoxy-D-glucose (FDG), fluoro-misonidazole (FMISO) and 3'deoxy-3-fluoro-thymidine deoxy-3-fluoro-thymidine (FLT) measured in tomography by broadcast(emission,issue)…
- Trial name
- RTEP4 (NCT01261585)
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Centre Henri Becquerel
Solid Neoplasms
Improving Informed Consent for Early Phase Anti-Cancer Trials
The purpose of the trial will be to test whether providing both a short summary PIS and a link to a set of online video modules will improve patient understanding (those considering early phase clinical trials) as measured on the…
- Trial name
- CONSENT (NCT04407676)
- Testing
- Summary PIS and Online Video Modules
- Where
- United Kingdom
- Volunteers
- 34 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Solid Tumor, Solid Tumor, Adult
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
The purpose of this study is to translate and tailor for Latinx participants a program called Communicating with Oncology Nurses about Values from the Outset (CONVO).
- Conditions
- Solid Tumor, Solid Tumor, Adult, Solid Tumor, Unspecified, Adult
- Trial name
- NCT04942717
- Testing
- CONVO intervention
- Where
- 5 sites in United States
- Volunteers
- 234 people
- Sponsor
- Memorial Sloan Kettering Cancer Center